LGND

#1403
Ligand Pharmaceuticals Inc.
225.0900 USD
-3.12%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
225.0900
225.0900
Faixa anual
175.8900
234.7600
Mudança diária
-3.12%
Mudança mensal
+8.22%
Mudança em 6 meses
+20.29%
Mudança anual
+20.29%
Fechamento anterior
232.3400
Abrir
225.0900
Bid
Ask
Mínimo
225.0900
High
225.0900
Volume
49
Abrir gráfico completo

Financials

Visão geral Relatórios Estatísticas Dividendos
Trimestral Ano
  • Market Capitalization 4.4886 B
  • Employee 47
  • Founded N/A
  • CEO N/A
  • Website www.ligand.com
  • Headquarter Delaware, United States
  • FIGI BBG000BKF014
  • Industry Biotecnologia
Receita total
Lucro líquido
Lucro básico por ação
Dívida total
Fluxo de caixa livre
Caixa e equivalentes de caixa
Índice preço/lucro
30.84
Índice preço/fluxo de caixa
14.31
Dividendos por ação
2.5
Rendimento de dividendos, %
1.32

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol. The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments. Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020.

Notícias